Science Explorer Interactive view Map

ImCare Biotech (United States)

Research works
4
▼ 64% vs 2013–17
Citations
9
2.5 per fractional work
Top-10% rate
3.4%
record average 16.5%
Open access
58%
world 28%

Not ranked overall: ImCare Biotech (United States) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.

Which research topics does ImCare Biotech (United States) publish most on?

By volume in 2022–2025: Cancer Research and Treatments, Cancer Immunotherapy and Biomarkers, Liver Disease Diagnosis and Treatment and Hepatocellular Carcinoma Treatment and Prognosis.

  1. 1 Cancer Research and Treatments Biotechnology 0 works
  2. 2 Cancer Immunotherapy and Biomarkers Oncology 0 works
  3. 3 Liver Disease Diagnosis and Treatment Epidemiology 0 works
  4. 4 Hepatocellular Carcinoma Treatment and Prognosis Hepatology 0 works
  5. 5 Hepatitis C virus research Hepatology 0 works
  6. 6 Metastasis and carcinoma case studies Pulmonary and Respiratory Medicine 0 works
  7. 7 Computational Drug Discovery Methods Computational Theory and Mathematics 0 works
  8. 8 Lymphoma Diagnosis and Treatment Pathology and Forensic Medicine 0 works
  9. 9 Artificial Intelligence in Healthcare Health Information Management 0 works
  10. 10 Scientific Computing and Data Management Information Systems and Management 0 works

How open and international is its research?

Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available58.3%not open41.7%

World: 28% of research is openly available.

with international co-authors9.5%domestic only90.5%

World: 19% is written across borders.

Other research institutions in Doylestown

All research institutions in Doylestown

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.